We are live on ! Find out more
FUSN icon

Fusion Pharmaceuticals

Delisted

FUSN was delisted on the 3rd of June, 2024.

31 hedge funds and large institutions have $89.5M invested in Fusion Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

2.24% more ownership

Funds ownership: 61.26% → 63.51% (+2.2%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9% less funds holding

Funds holding: 34 → 31 (-3)

40% less capital inflows, than outflows

Capital inflows: $770K | Capital outflows: $1.27M

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
31
Holders Change
-3
Holders Change %
-8.82%
% of All Funds
0.5%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
2
Increased
5
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

FUSN Hedge Fund Activity: Q4 2022 in Review

31 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals (FUSN) for Q4 2022, worth a combined $89.5M — up 11% from $80.3M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of FUSN and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was UBS O'Connor, adding an estimated $431K. The largest seller was Fidelity Investments, cutting an estimated $883K.

  • 31 institutional investors held Fusion Pharmaceuticals (FUSN) as of Q4 2022, down from 34 in Q3 2022.
  • Funds reported $89.5M of Fusion Pharmaceuticals stock for Q4 2022, up 11% quarter-over-quarter.
  • 2 funds opened new Fusion Pharmaceuticals positions in Q4 2022 and 5 closed out, a net change of -3 holders.
  • The largest Fusion Pharmaceuticals buyer in Q4 2022 was UBS O'Connor, an estimated $431K added.
  • The largest Fusion Pharmaceuticals seller in Q4 2022 was Fidelity Investments, an estimated $883K sold.

Based on aggregated 13F filings for Q4 2022.